These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT. Lincoln NB; Bradshaw LE; Constantinescu CS; Day F; Drummond AE; Fitzsimmons D; Harris S; Montgomery AA; das Nair R Health Technol Assess; 2020 Jan; 24(4):1-182. PubMed ID: 31934845 [TBL] [Abstract][Full Text] [Related]
23. Self-management of fatigue in rheumatoid arthritis: a randomised controlled trial of group cognitive-behavioural therapy. Hewlett S; Ambler N; Almeida C; Cliss A; Hammond A; Kitchen K; Knops B; Pope D; Spears M; Swinkels A; Pollock J Ann Rheum Dis; 2011 Jun; 70(6):1060-7. PubMed ID: 21540202 [TBL] [Abstract][Full Text] [Related]
24. Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Okkersen K; Jimenez-Moreno C; Wenninger S; Daidj F; Glennon J; Cumming S; Littleford R; Monckton DG; Lochmüller H; Catt M; Faber CG; Hapca A; Donnan PT; Gorman G; Bassez G; Schoser B; Knoop H; Treweek S; van Engelen BGM; Lancet Neurol; 2018 Aug; 17(8):671-680. PubMed ID: 29934199 [TBL] [Abstract][Full Text] [Related]
25. Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. Piatkowski J; Kern S; Ziemssen T J Altern Complement Med; 2009 May; 15(5):507-11. PubMed ID: 19422286 [TBL] [Abstract][Full Text] [Related]
26. Effects of pulsed electromagnetic field therapy on fatigue, walking performance, depression, and quality of life in adults with multiple sclerosis: a randomized placebo-controlled trial. Granja-Domínguez A; Hochsprung A; Luque-Moreno C; Magni E; Escudero-Uribe S; Heredia-Camacho B; Izquierdo-Ayuso G; Heredia-Rizo AM Braz J Phys Ther; 2022; 26(5):100449. PubMed ID: 36283240 [TBL] [Abstract][Full Text] [Related]
27. Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis. Thomas PW; Thomas S; Kersten P; Jones R; Nock A; Slingsby V; Green C; Baker R; Galvin K; Hillier C BMC Neurol; 2010 Jun; 10():43. PubMed ID: 20553617 [TBL] [Abstract][Full Text] [Related]
28. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial. Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350 [TBL] [Abstract][Full Text] [Related]
29. Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial. Barkham M; Saxon D; Hardy GE; Bradburn M; Galloway D; Wickramasekera N; Keetharuth AD; Bower P; King M; Elliott R; Gabriel L; Kellett S; Shaw S; Wilkinson T; Connell J; Harrison P; Ardern K; Bishop-Edwards L; Ashley K; Ohlsen S; Pilling S; Waller G; Brazier JE Lancet Psychiatry; 2021 Jun; 8(6):487-499. PubMed ID: 34000240 [TBL] [Abstract][Full Text] [Related]
30. Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure. Sumowski JF; Leavitt VM Arch Phys Med Rehabil; 2014 Jul; 95(7):1298-302. PubMed ID: 24561056 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial. Kiropoulos L; Kilpatrick T; Kalincik T; Churilov L; McDonald E; Wijeratne T; Threader J; Rozenblat V; O’Brien-Simpson N; Van Der Walt A; Taylor L Trials; 2020 Jan; 21(1):100. PubMed ID: 31959224 [TBL] [Abstract][Full Text] [Related]
32. Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trial. Jongen PJ; van Mastrigt GA; Heerings M; Visser LH; Ruimschotel RP; Hussaarts A; Duyverman L; Valkenburg-Vissers J; Cornelissen J; Bos M; van Droffelaar M; Donders R PLoS One; 2019; 14(10):e0223482. PubMed ID: 31600271 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA; BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583 [TBL] [Abstract][Full Text] [Related]
34. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A; Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925 [TBL] [Abstract][Full Text] [Related]
35. A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the "COMBO-MS" trial. Kratz AL; Alschuler KN; Ehde DM; von Geldern G; Little R; Kulkarni S; Pickup K; Braley TJ Contemp Clin Trials; 2019 Sep; 84():105821. PubMed ID: 31400515 [TBL] [Abstract][Full Text] [Related]
36. Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis. Freeman J; Hendrie W; Jarrett L; Hawton A; Barton A; Dennett R; Jones B; Zajicek J; Creanor S Lancet Neurol; 2019 Aug; 18(8):736-747. PubMed ID: 31301748 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Nourbakhsh B; Revirajan N; Morris B; Cordano C; Creasman J; Manguinao M; Krysko K; Rutatangwa A; Auvray C; Aljarallah S; Jin C; Mowry E; McCulloch C; Waubant E Lancet Neurol; 2021 Jan; 20(1):38-48. PubMed ID: 33242419 [TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908 [TBL] [Abstract][Full Text] [Related]